Overview
A compounded multi-peptide blend rather than a single molecule, combining KPV, larazotide, GHK-Cu, BPC-157 and TB-500. It has no independent research base of its own — the evidence available applies to each constituent studied separately.
Mechanism of Action
KLOW is a formulation, not a discrete compound. Any activity attributed to it is the sum of its five constituents, and no published study has characterised the combination as a unit.
KPV, the C-terminal tripeptide of alpha-MSH, is studied for suppression of NF-κB-driven inflammatory signalling, particularly in gut mucosa.
Larazotide is a zonulin antagonist studied in intestinal permeability research, where it is reported to support tight-junction integrity.
GHK-Cu delivers copper for lysyl oxidase-dependent collagen cross-linking and is studied in skin remodelling; BPC-157 is studied in tissue repair and angiogenesis models; TB-500 is the synthetic fragment of thymosin beta-4 studied in actin regulation and cell migration.
Areas Being Studied
- Gut barrier and intestinal permeability research
- Inflammatory signalling
- Tissue repair and wound-healing models
- Skin and connective-tissue remodelling
Listing a research area does not imply efficacy, approval, or suitability for any use.
Research Summary
- There are no published studies of the KLOW combination itself. Every citation in circulation refers to one of its individual components.
- Larazotide is the most clinically advanced constituent, having reached phase 3 evaluation in coeliac disease research, where the primary endpoint was not met in the reported trial.
- KPV has a substantive preclinical literature in colitis models; GHK-Cu has a long-standing dermatological research base.
- BPC-157 and TB-500 remain almost entirely preclinical, with no completed controlled human trials — a limitation that carries over to any blend containing them.
Potential Adverse Effects Reported in Research
- Because the blend has not been studied, its adverse-effect profile is unknown; only constituent-level observations exist.
- Component reports include injection-site reactions, transient gastrointestinal effects, and local irritation from copper-containing peptides.
- Combining five peptides in a single preparation raises formulation-stability and interaction questions that the literature does not address.
- Reviews of compounded multi-peptide preparations note the absence of any safety or pharmacokinetic characterisation.
Reconstitution Basics
Supplied as a compounded lyophilised blend, typically with a blue tint from the GHK-Cu component. Because the constituents differ in stability and pH sensitivity, laboratory documentation notes that blend behaviour after reconstitution is less predictable than for a single peptide.
Bacteriostatic water
Sterile water containing roughly 0.9% benzyl alcohol as a preservative, which inhibits bacterial growth in multi-access vials.
Sterile technique
Laboratory documentation describes disinfecting the stopper, using a fresh sterile needle for each access, and avoiding contact with non-sterile surfaces.
After reconstitution
Solutions are refrigerated, protected from light, and not subjected to repeated freeze–thaw cycles.
This section is educational background on laboratory handling. It is not an instruction or protocol.
Open the reconstitution calculator →Dosing & Reconstitution Guide
The most widely documented KLOW presentation is a single 80 mg vial holding four peptides in a fixed 5:1:1:1 ratio — GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg and KPV 10 mg (some compounders also add larazotide). Because all components share one vial they are reconstituted and measured together and cannot be adjusted independently. Documented handling adds 3.0 mL bacteriostatic water for ~26.67 mg/mL of total blend, where 1 insulin unit ≈ 267 mcg. The combination itself has not been validated in any human trial.
Protocol overview
- Reconstitute the single 80 mg vial with 3.0 mL bacteriostatic water → ~26.67 mg/mL of total blend; units = total mcg ÷ 267.
- Once-daily subcutaneous administration is the documented cadence, for 8–12 weeks (occasionally ~16).
- The 62.5% GHK-Cu / 12.5% each BPC-157, KPV and TB-500 split is fixed — per-component amounts scale with the total volume drawn.
- One 80 mg vial at 3.0 mL covers roughly 15–30 daily doses depending on phase; an 8-week course typically uses ~2–3 vials, 16 weeks ~4–5.
- Blend ratios and component lists vary between compounders — two KLOW vials are not necessarily equivalent.
- Constituents have very different half-lives, and no safety or interaction data exists for the combination specifically.
Dosing protocol — standard titration
| Phase | Reported dose | Notes |
|---|---|---|
| Weeks 1–2 | 2,667 mcg total blend once daily~10 units (0.10 mL) at ~26.67 mg/mL; ≈1,667 mcg GHK-Cu + ~333 mcg each of BPC-157, KPV and TB-500. | ~10 units (0.10 mL) at ~26.67 mg/mL; ≈1,667 mcg GHK-Cu + ~333 mcg each of BPC-157, KPV and TB-500. |
| Weeks 3–6 | 4,000 mcg total blend once daily~15 units (0.15 mL). | ~15 units (0.15 mL). |
| Weeks 7–12 | 5,333 mcg total blend once daily~20 units (0.20 mL); courses run 8–12 weeks, sometimes extended to ~16. | ~20 units (0.20 mL); courses run 8–12 weeks, sometimes extended to ~16. |
Dosing protocol — gradual titration
| Phase | Reported dose | Notes |
|---|---|---|
| Week 1 | 1,333 mcg total blend, alternate days~5 units; slower entry given four active components. | ~5 units; slower entry given four active components. |
| Weeks 2–4 | 2,667 mcg total blend once daily~10 units; hold before any increase. | ~10 units; hold before any increase. |
| Weeks 5–12 | 4,000 → 5,333 mcg total blend once daily~15 → 20 units, increased only where tolerability is uneventful. | ~15 → 20 units, increased only where tolerability is uneventful. |
Schedules summarise what appears in published studies, trial protocols or manufacturer documentation. They are reference material, not a recommendation.
Where to Buy Compounds & Supplies
External link. PepDex does not sell products and does not endorse any supplier.
Supplies needed
Lyophilised peptide vial
Sealed vial with an intact stopper and a legible mass label (mg or mcg).
Bacteriostatic water
Sterile water with ~0.9% benzyl alcohol, used where a vial will be accessed more than once. Sterile water for injection is used for single-access work.
Reconstitution syringe
A 1–3 mL syringe with a larger-gauge needle for drawing and transferring solvent.
Insulin syringe (U-100)
Fine-gauge syringe graduated in units; 100 units = 1 mL. Used for accurate small-volume measurement.
Alcohol prep pads
70% isopropyl swabs for disinfecting both vial stoppers before every access.
Sharps container
Rigid, puncture-resistant container for single-use needle disposal.
Refrigeration and light protection
2–8 °C storage plus an opaque box or the original carton for reconstituted vials.
Labels
Date of reconstitution, resulting concentration and compound name on every vial.
Reconstitution steps
- 01
Bring the vial to room temperature
Lyophilised powder is allowed to equilibrate out of the refrigerator before the stopper is pierced, which reduces condensation inside the vial.
- 02
Disinfect both stoppers
The peptide vial and the bacteriostatic water vial are each swabbed with 70% isopropyl alcohol and allowed to air dry.
- 03
Draw the calculated solvent volume
Solvent volume is chosen to produce a convenient concentration — the reconstitution calculator converts vial mass and solvent volume into concentration and syringe units.
- 04
Add the solvent slowly down the vial wall
The stream is directed against the glass rather than onto the powder cake. Peptides are shear-sensitive and direct jetting is avoided.
- 05
Dissolve without shaking
The vial is left to stand, then gently swirled or rolled. Shaking introduces foam and mechanical stress that can denature peptide chains.
- 06
Inspect the solution
Documentation describes checking for a clear, particle-free solution. Cloudiness, visible particulate or discolouration is treated as a failed preparation.
- 07
Label and refrigerate
The vial is labelled with compound, concentration and date, then stored at 2–8 °C protected from light.
Storage instructions
- Before reconstitution: lyophilised blend stored at −20 °C (−4 °F), protected from light.
- After reconstitution: refrigerate at 2–8 °C (35.6–46.4 °F); do not freeze the solution — freeze–thaw can denature the peptides.
- Copper content makes the solution light-sensitive; keep in the original carton or an opaque box.
- Label each vial with the date and resulting concentration; in-use periods are commonly cited as ~30 days refrigerated.
Half-Life
Not characterised as a blend
No pharmacokinetic data exist for the combination. Constituent half-lives differ widely, from minutes for KPV to hours for TB-500, so a single figure is not meaningful.
Storage
- Before reconstitution
- Lyophilised powder stored frozen at −20 °C.
- After reconstitution
- Refrigerated at 2–8 °C after reconstitution.
- Light protection
- Protected from light; the copper component is additionally oxidation-sensitive.
- Shelf-life considerations
- Shorter working windows are generally described than for single peptides, given mixed-component stability.
Frequently Asked Questions
References
Related peptides
KPV
A tripeptide corresponding to the C-terminal sequence of alpha-melanocyte-stimulating hormone. It is studied for anti-inflammatory activity without the pigmentation effects associated with the parent hormone.
BPC-157
A synthetic pentadecapeptide derived from a sequence identified in human gastric juice. It is one of the most widely studied peptides in preclinical tissue-repair research, though human clinical data remains very limited.
GHK-Cu
A naturally occurring copper-binding tripeptide found in human plasma. It is among the best characterised peptides in dermatological and wound-healing research.
Educational reference only. Figures are compiled from published research literature. PepDex does not provide medical advice, dosing recommendations, or instructions for use.